Online inquiry

IVTScrip™ mRNA-Anti-PDCD1, BI-754091(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ4142MR)

This product GTTS-WQ4142MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets PDCD1 gene. The antibody can be applied in Non-Small Cell Lung Cancers (NSCLC) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_005018.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 5133
UniProt ID Q15116
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PDCD1, BI-754091(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ4142MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ14186MR IVTScrip™ mRNA-Anti-ANGPT2, REGN-910(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA REGN-910
GTTS-WQ6179MR IVTScrip™ mRNA-Anti-CD40, CP-870893(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CP-870893
GTTS-WQ11750MR IVTScrip™ mRNA-Anti-CTLA4, MK-1308(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MK-1308
GTTS-WQ1841MR IVTScrip™ mRNA-Anti-IL17A, AG1-25(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA AG1-25
GTTS-WQ13349MR IVTScrip™ mRNA-Anti-PDCD1, PF-06801591(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA PF-06801591
GTTS-WQ5731MR IVTScrip™ mRNA-Anti-CEACAM5, CEA-IL-2v(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CEA-IL-2v
GTTS-WQ3791MR IVTScrip™ mRNA-Anti-Factor VIIa substitute, BAY-86-6150(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA BAY-86-6150
GTTS-WQ8400MR IVTScrip™ mRNA-Anti-MS4A1, HS006(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA HS006
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW